Exercise of Option Year SPE2D217D0060P00006
ID: SPE2D217D0060Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/599bf13b103e49739fe9cc68d2590112/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is exercising the option for the Hydrochlorothiazide National Contract. Hydrochlorothiazide is a medication used to treat high blood pressure and fluid retention. This procurement is for the supply of Hydrochlorothiazide, which is a medical and surgical instrument, equipment, and supply. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 2157376877.

    Point(s) of Contact
    Denise Taubman
    (215) 737-6877
    denise.taubman@dla.mil
    Lifecycle
    Title
    Type
    EXERCISE OF OPTION HYDROCHLOROTHIAZIDE NATIONAL CONTRACT
    Currently viewing
    Special Notice
    Similar Opportunities
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used for treating high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties can contact Catherine Gilbert for more information. The solicitation is projected to be issued in December 2019.
    Telmisartan Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Telmisartan Tablets. Telmisartan Tablets are pharmaceutical preparations used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney problems in certain patients. The tablets will be available in 20MG, 40MG, and 80MG strengths, packaged in 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide Telmisartan Tablets to Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. Interested parties can contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions/comments. The solicitation is projected to be issued in August of 2024.
    Sertraline HCL National Contract
    Active
    Dept Of Defense
    Presolicitation notice for a national contract for Sertraline HCL. Sertraline HCL is a medical/dental/veterinary equipment/supply used for the treatment of depression, panic attacks, obsessive-compulsive disorder, post-traumatic stress disorder, and social anxiety disorder. Contact Danielle Delaney at Danielle.Delaney@dla.mil or 215-737-2998 for more information.
    Potassium Chloride Extended Release Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for Potassium Chloride Extended Release Tablets under solicitation number SPE2D2-24-R-0013. This procurement aims to acquire pharmaceutical products in various quantities, ensuring that suppliers meet federal standards for quality and compliance. Potassium Chloride is a critical medication used for treating and preventing potassium deficiency, making this solicitation vital for maintaining health standards within military and defense operations. Interested vendors must submit their offers electronically through the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of October 10, 2024. For further inquiries, potential bidders can contact Ryan Guarnere at ryan.guarnere@dla.mil or Jason Wray at jason.wray@dla.mil.
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    MODIFICATION TO ENALAPRIL NATIONAL CONTRACT
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking a modification to the ENALAPRIL NATIONAL CONTRACT. This modification aims to incorporate additional clauses into the existing contract. The ENALAPRIL NATIONAL CONTRACT is typically used for the procurement of enalapril, a medication used to treat high blood pressure and heart failure. The modification will ensure that the contract includes all necessary terms and conditions for the procurement of enalapril. For more information, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.
    Fluconazole - SPE2D221-D-0125-P00012 - Final Option Notice
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), has issued a special notice regarding the contract modification for Fluconazole under contract number SPE2D221-D-0125-P00012. This modification announces the exercise of the final option for the procurement of this pharmaceutical product, which is critical for various medical applications within military healthcare. Interested parties can reach out to the primary contact, Courtney Hunter-Stangler, at Courtney.Hunter-Stangler@dla.mil or by phone at 215-737-6845, or to the secondary contact, Jason Wray, at jason.wray@dla.mil or 215-737-0614, for further details regarding this opportunity.
    Azithromycin Suspension
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Azithromycin Suspension, specifically in 200MG/5ML bottles of 15ML, 22.5ML, and 30ML sizes. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for various healthcare needs within the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for October 2024, and can contact Kahaun Vicks at 215-737-0652 or Kahaun.Vicks@dla.mil for further inquiries.
    Finasteride Tablets
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.